Developing a vaccine to target specific antibodies against HIV-1.

HIV-1 Env immunogens that target unmutated common ancestor antibodies (UCAs) of broadly neutralizing antibodies (bnAbs) reactive with multiple HIV-1 envelope epitopes

NIH-funded research Duke University · NIH-11078956

This study is exploring a new way to help the immune system create powerful antibodies that can fight off different strains of HIV-1, using a special vaccination method that encourages the body to develop these antibodies naturally.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionDuke University NIH-funded
Lab location1 site (Durham, United States)
Project IDNIH-11078956 on NIH RePORTER

What this research studies

This research focuses on creating immunogens that can stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV-1. It aims to mimic the natural evolution of the virus by using sequential vaccination strategies that engage unmutated common ancestor antibodies (UCAs). By targeting these UCAs, the goal is to enhance the body's ability to generate effective bnAbs that can recognize and neutralize multiple strains of HIV-1. The approach involves developing specific envelope proteins that can activate these rare antibody precursors in the immune system.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals at risk of HIV infection or those who are HIV-negative but may benefit from preventive vaccination.

Not a fit: Patients who are already HIV-positive or have advanced HIV/AIDS may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of an effective HIV vaccine that provides broad protection against various strains of the virus.

How similar studies have performed: Other research has shown promise in targeting similar antibody precursors, but this approach is still considered novel in the context of HIV vaccine development.

Where this research is happening

Durham, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.